Victory Capital Management Inc. Raises Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Victory Capital Management Inc. lifted its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 1,091.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 122,138 shares of the company's stock after buying an additional 111,889 shares during the quarter. Victory Capital Management Inc.'s holdings in GoodRx were worth $568,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Point72 Asset Management L.P. acquired a new stake in shares of GoodRx during the third quarter worth about $11,295,000. Rubric Capital Management LP increased its position in GoodRx by 25.2% during the third quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company's stock worth $32,479,000 after buying an additional 943,226 shares during the period. Franklin Resources Inc. purchased a new stake in GoodRx in the third quarter valued at approximately $5,675,000. Pier Capital LLC acquired a new stake in shares of GoodRx in the third quarter valued at approximately $3,259,000. Finally, Barclays PLC grew its position in shares of GoodRx by 1,316.1% during the third quarter. Barclays PLC now owns 140,113 shares of the company's stock worth $973,000 after acquiring an additional 130,219 shares during the last quarter. Institutional investors and hedge funds own 63.77% of the company's stock.

GoodRx Price Performance

GoodRx stock traded down $0.09 during trading hours on Tuesday, hitting $4.55. The stock had a trading volume of 1,087,719 shares, compared to its average volume of 1,355,412. GoodRx Holdings, Inc. has a 1-year low of $4.09 and a 1-year high of $9.26. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of -151.67, a PEG ratio of 2.46 and a beta of 1.25. The stock's fifty day moving average is $4.75 and its two-hundred day moving average is $5.37. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48.

Remove Ads

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Morgan Stanley decreased their price target on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a research note on Tuesday, December 17th. Wells Fargo & Company lowered their target price on shares of GoodRx from $9.00 to $8.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Citigroup cut their price target on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating for the company in a report on Friday, January 10th. KeyCorp reduced their price objective on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Finally, Mizuho initiated coverage on GoodRx in a research report on Wednesday, December 4th. They set a "neutral" rating and a $5.00 target price on the stock. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $8.18.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.